Korean J Gastroenterol.  2012 Feb;59(2):141-179. 10.4166/kjg.2012.59.2.141.

Guidelines for the Management of Crohn's Disease

• Ye BD
• Yang SK
• Shin SJ
• Lee KM
• Jang BI
• Cheon JH
• Choi CH
• Kim YH
• Lee H
• IBD Study Group of the Korean Association for the Study of the Intestinal Diseases

• KMID: 1792823
• DOI: http://doi.org/10.4166/kjg.2012.59.2.141

Abstract

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with uncertain etiopathogenesis. CD can involve any site of gastrointestinal tract from the mouth to anus and is associated with serious complications such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies are currently applied for diverse clinical situations of CD. However, a lot of decisions on the management of CD are made depending on the personal experiences and personal dicision of physicians. To suggest preferable approaches to diverse problems of CD and to minimize the variations according to physicians, guidelines for the management of CD are needed. Therefore, IBD Study Group of the Korean Association for the Study of the Intestinal Diseases has set out to develop the guidelines for the management of CD in Korea. These guidelines were developed using the adaptation methods and encompass the treatment of inflammatory disease, stricturing disease, and penetrating disease. The guidelines also cover the indication of surgery, prevention of recurrence after surgery, and CD in pregnancy and lactation. These are the first Korean guidelines for the management of CD and the update with further scientific data and evidences is needed.

Keyword

Crohn's disease; Treatment; Guideline

MeSH Terms

6-Mercaptopurine/analogs & derivatives/therapeutic use
Anti-Inflammatory Agents/therapeutic use
Antibodies, Monoclonal/therapeutic use
Antimetabolites, Antineoplastic/therapeutic use
Budesonide/therapeutic use
Crohn Disease/*drug therapy/pathology
Databases, Factual
Female
Fistula/therapy
Humans
Intestinal Perforation/surgery/therapy
Male
Mesalamine/therapeutic use
Methotrexate/therapeutic use
Prednisolone/therapeutic use
Pregnancy
Recurrence
Risk Factors
Severity of Illness Index
Sulfasalazine/therapeutic use

Figure

• 

  Fig. 1 Workflow of guideline development.

• 

  Fig. 2 Searching, evaluation and selection of previous guidelines for the management of Crohn's disease. NHS, National Health Service.

• 

  Fig. 3 Algorithm for the treatment of active Crohn's disease. 5-ASA, 5-aminosalicylic acid; 6-MP, 6-mercaptopurine; AZA, azathioprine; MTX, methotrexate; TNF, tumor necrosis factor.

Reference

1. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008. 14:542–549.

2. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008. 103:3167–3182.

3. Ye BD, Jang BI, Jeen YT, Lee KM, Kim JS, Yang SK. IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Diagnostic guideline of Crohn's disease. Korean J Gastroenterol. 2009. 53:161–176.

4. Fervers B, Burgers JS, Haugh MC, et al. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. Int J Qual Health Care. 2006. 18:167–176.

5. Brouwers MC, Kho ME, Browman GP, et al. AGREE Next Steps Consortium. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ. 2010. 182:1045–1052.

6. Brouwers MC, Kho ME, Browman GP, et al. AGREE Next Steps Consortium. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ. 2010. 182:E472–E478.

7. Sachar DB. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis. 2003. 9:205–209.

8. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009. 104:465–483.

9. Dignass A, Van Assche G, Lindsay JO, et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010. 4:28–62.

10. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976. 70:439–444.

11. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980. 1:514.

12. Van Assche G, Dignass A, Panes J, et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010. 4:7–27.

13. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999. 117:761–769.

14. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002. 359:1541–1549.

15. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002. 122:512–530.

16. Stange EF, Travis SP, Vermeire S, et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006. 55:Suppl 1. i1–i15.

17. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000. 6:8–15.

18. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006. 55:749–753.

19. Greenberg GR, Feagan BG, Martin F, et al. Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn's disease. N Engl J Med. 1994. 331:836–841.

20. Thomsen OO, Cortot A, Jewell D, et al. International Budesonide-Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med. 1998. 339:370–374.

21. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2005. (4):CD000296.

22. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002. 16:1509–1517.

23. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994. 331:842–845.

24. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004. 2:379–388.

25. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000. (2):CD000067.

26. Fraser AG. Methotrexate: first-line or second-line immunomodulator? Eur J Gastroenterol Hepatol. 2003. 15:225–231.

27. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006. 130:940–987.

28. Targan SR, Hanauer SB, van Deventer SJ, et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997. 337:1029–1035.

29. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007. 146:829–838.

30. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004. 99:91–96.

31. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008. 135:1493–1499.

32. D'Haens G, Baert F, van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group. North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008. 371:660–667.

33. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010. 362:1383–1395.

34. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984. 86:249–266.

35. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979. 77:847–869.

36. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study. Scand J Gastroenterol. 1974. 9:549–554.

37. Van Hees PA, Van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut. 1981. 22:404–409.

38. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999. 116:521–526.

39. Singleton JW, Hanauer SB, Gitnick GL, et al. Pentasa Crohn's Disease Study Group. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology. 1993. 104:1293–1301.

40. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol. 1994. 19:278–282.

41. Vermeire S, Louis E, Carbonez A, et al. Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002. 97:2357–2363.

42. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2001. (3):CD000542.

43. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991. 32:1071–1075.

44. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007. 132:52–65.

45. Sandborn WJ, Feagan BG, Stoinov S, et al. PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007. 357:228–238.

46. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009. 136:441–450.

47. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002. 122:1808–1814.

48. Tremaine WJ. Gastroduodenal Crohn's disease: medical management. Inflamm Bowel Dis. 2003. 9:127–128.

49. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995. 30:699–706.

50. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006. 130:650–656.

51. Wolters FL, Russel MG, Sijbrandij J, et al. European Collaborative study group on Inflammatory Bowel Disease (EC-IBD). Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006. 55:510–518.

52. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol. 2008. 43:948–954.

53. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000. (2):CD000545.

54. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev. 2005. (1):CD003459.

55. D'Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011. 106:199–212.

56. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008. 134:1861–1868.

57. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009. 30:210–226.

58. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010. 59:1363–1368.

59. Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol. 2010. 105:1142–1149.

60. Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther. 2005. 21:921–931.

61. Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology. 1996. 110:424–431.

62. Breuer-Katschinski BD, Holländer N, Goebell H. Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol. 1996. 8:225–228.

63. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2005. (1):CD003715.

64. Nagy F, Molnar T, Szepes Z, Farkas K, Nyari T, Lonovics J. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol. 2008. 14:4342–4346.

65. Lémann M, Mary JY, Colombel JF, et al. Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005. 128:1812–1818.

66. Treton X, Bouhnik Y, Mary JY, et al. Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2009. 7:80–85.

67. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000. 95:3150–3156.

68. Lémann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000. 95:1730–1734.

69. Fraser AG, Morton D, McGovern D, Travis S, Jewell DP. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther. 2002. 16:693–697.

70. Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut. 2008. 57:A66.

71. Waugh AW, Garg S, Matic K, et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther. 2010. 32:1129–1134.

72. Travis SP, Stange EF, Lémann M, et al. for the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis. 2008. 2:24–62.

73. Feagan BG. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. Clin Gastroenterol Hepatol. 2004. 2:376–378.

74. Logan RF, van Staa TP. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2003. 52:1530.

75. Loftus EV Jr, Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004. 19:179–189.

76. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004. 126:1733–1739.

77. Mahmud N, Kamm MA, Dupas JL, et al. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut. 2001. 49:552–556.

78. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology. 2004. 126:1257–1269.

79. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2005. (4):CD000296.

80. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2003. (4):CD000301.

81. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003. 125:320–327.

82. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009. 58:501–508.

83. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006. 4:621–630.

84. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008. 134:929–936.

85. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. The Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut. 1997. 41:209–214.

86. Greenberg GR, Feagan BG, Martin F, et al. Canadian Inflammatory Bowel Disease Study Group. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology. 1996. 110:45–51.

87. Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996. 39:82–86.

88. Gross V, Andus T, Ecker KW, et al. The Budesonide Study Group. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. Gut. 1998. 42:493–496.

89. Ferguson A, Campieri M, Doe W, Persson T, Nygård G. Global Budesonide Study Group. Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Aliment Pharmacol Ther. 1998. 12:175–183.

90. Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther. 2000. 14:1419–1428.

91. Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005. 100:1780–1787.

92. Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009. (1):CD002913.

93. Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut. 2001. 48:186–190.

94. Schoon EJ, Bollani S, Mills PR, et al. Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol. 2005. 3:113–121.

95. Cino M, Greenberg GR. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol. 2002. 97:915–921.

96. Sandborn WJ, Tremaine WJ, Wolf DC, et al. North American Azathioprine Study Group. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology. 1999. 117:527–535.

97. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009. (1):CD000067.

98. Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet. 1971. 2:944–947.

99. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis. 1975. 20:721–726.

100. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut. 2001. 48:591–592.

101. Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004. 2:731–743.

102. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007. 46:187–208.

103. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005. 22:1–16.

104. Travis SP, Stange EF, Lémann M, et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006. 55:Suppl 1. i16–i35.

105. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989. 111:641–649.

106. Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol. 2003. 37:220–225.

107. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004. 13:563–567.

108. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol. 2005. 100:1121–1125.

109. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000. 118:705–713.

110. Schwab M, Schäffeler E, Marx C, et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics. 2002. 12:429–436.

111. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002. 50:485–489.

112. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993. 34:1081–1085.

113. Sturdevant RA, Singleton JW, Deren JL, Law DH, McCleery JL. Azathioprine-related pancreatitis in patients with Crohn's disease. Gastroenterology. 1979. 77:883–886.

114. Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther. 2004. 20:843–850.

115. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 1991. 101:39–46.

116. Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996. 347:215–219.

117. Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion. 2000. 62:249–254.

118. de Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2004. 16:207–212.

119. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995. 123:132–142.

120. Gisbert JP, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008. 103:1783–1800.

121. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998. 129:716–718.

122. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999. 91:2001–2008.

123. Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am J Gastroenterol. 2006. 101:2769–2776.

124. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997. 62:60–73.

125. McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999. 9:773–776.

126. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002. 51:143–146.

127. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2004. 20:593–599.

128. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000. 118:1025–1030.

129. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006. 24:715–729.

130. Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther. 2000. 14:1561–1565.

131. Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci. 2000. 45:1810–1813.

132. Domènech E, Nos P, Papo M, et al. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand J Gastroenterol. 2005. 40:52–55.

133. Kim DU, Kim YH, Kim BJ, et al. The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease. Hepatogastroenterology. 2009. 56:1395–1402.

134. Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J Gastroenterol. 2008. 51:291–297.

135. Lee HJ, Yang SK, Kim KJ, et al. The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with Crohn's disease. Intest Res. 2009. 7:22–31.

136. Kim JH, Cheon JH, Hong SS, et al. Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study. J Clin Gastroenterol. 2010. 44:e242–e248.

137. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005. 54:1121–1125.

138. Feagan BG, Rochon J, Fedorak RN, et al. The North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med. 1995. 332:292–297.

139. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999. 46:1724–1729.

140. Feagan BG, Fedorak RN, Irvine EJ, et al. North American Crohn's Study Group Investigators. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med. 2000. 342:1627–1632.

141. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol. 1997. 36:86–90.

142. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther. 2003. 18:57–63.

143. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004. 43:267–271.

144. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med. 1989. 321:845–850.

145. Feagan BG, McDonald JW, Rochon J, Gillies R, et al. The Canadian Crohn's Relapse Prevention Trial Investigators. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med. 1994. 330:1846–1851.

146. Jewell DP, Lennard-Jones JE, Lowes J, et al. Oral cyclosporin for chronic active Crohn's disease: A multi-centre controlled trial. Eur J Gastroenterol Hepatol. 1994. 6:499–505.

147. Stange EF, Modigliani R, Peña AS, Wood AJ, Feutren G, Smith PR. The European Study Group. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology. 1995. 109:774–782.

148. Santos JV, Baudet JA, Casellas FJ, Guarner LA, Vilaseca JM, Malagelada JR. Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. Short- and long-term results. J Clin Gastroenterol. 1995. 20:207–210.

149. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol. 1998. 93:442–448.

150. Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, Pajares Garcia JM, Mate-Jimenez J. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterology. 1999. 46:2265–2268.

151. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997. 92:876–879.

152. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1998. 93:1860–1866.

153. Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther. 2001. 15:371–377.

154. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006. 130:323–333.

155. Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005. 129:807–818.

156. Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010. 8:688–695.

157. Sandborn WJ, Colombel JF, Enns R, et al. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005. 353:1912–1925.

158. Targan SR, Feagan BG, Fedorak RN, et al. International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology. 2007. 132:1672–1683.

159. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008. 6:1370–1377.

160. Sandborn WJ, Feagan BG, Fedorak RN, et al. Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008. 135:1130–1141.

161. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007. 56:1232–1239.

162. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007. 357:239–250.

163. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008. (1):CD006893.

164. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003. 348:601–608.

165. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007. 56:1226–1231.

166. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004. 2:542–553.

167. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004. 126:402–413.

168. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007. 44:265–267.

169. Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010. 8:655–659.

170. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005. 353:362–368.

171. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001. 345:1098–1104.

172. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003. 48:2122–2127.

173. Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clin North Am. 2006. 35:857–866.

174. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003. 124:917–924.

175. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004. 126:1593–1610.

176. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004. 126:19–31.

177. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009. 7:874–881.

178. Van Assche G, Dignass A, Reinisch W, et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis. 2010. 4:63–101.

179. Kim HD, Kim CG, Kim JW, et al. Clinical features and therapeutic responses of perianal lesions in Crohn's disease. Korean J Gastroenterol. 2003. 42:128–133.

180. Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980. 79:599.

181. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology. 1982. 83:383–387.

182. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol. 1984. 79:533–540.

183. Solomon MJ, McLeod RS, O'Connor BI, Steinhart AH, Greenberg GR, Cohen Z. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol. 1993. 7:571–573.

184. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009. 15:17–24.

185. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol. 1993. 88:1198–1205.

186. Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn's disease: a case series. Aliment Pharmacol Ther. 2003. 18:1003–1008.

187. Sandborn W. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam Bowel Dis. 1995. 1:48–63.

188. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003. 125:380–388.

189. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999. 340:1398–1405.

190. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004. 350:876–885.

191. Sands BE, Blank MA, Patel K, van Deventer SJ. ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study. Clin Gastroenterol Hepatol. 2004. 2:912–920.

192. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005. 128:862–869.

193. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000. 95:3490–3497.

194. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001. 96:722–729.

195. Lee KM, Kim JS, Shin DH, et al. Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication. Korean J Gastroenterol. 2004. 44:259–266.

196. Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea. Korean J Gastroenterol. 2005. 46:48–55.

197. Kim SH, Yang S, Kim KJ, et al. Efficacy of infliximab in the treatment of Korean patients with Crohns' disease. Korean J Gastroenterol. 2009. 54:108–116.

198. Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009. 58:940–948.

199. Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. Treatment of Crohn's disease with certolizumab pegol. Expert Rev Clin Immunol. 2007. 3:683–694.

200. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003. 125:1508–1530.

201. Irvine EJ. McMaster IBD Study Group. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. J Clin Gastroenterol. 1995. 20:27–32.

202. Chung CS, Lee DK, George BD, Mortensen NJ. Clinical outcome of a rectovaginal fistula in Crohn's disease. J Korean Soc Coloproctol. 2007. 23:10–15.

203. Graadal O, Nygaard K. Crohn disease. Long-term effects of surgical treatment. Tidsskr Nor Laegeforen. 1994. 114:1603–1605.

204. Kim NK, Senagore AJ, Luchtefeld MA, et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg. 1997. 63:627–633.

205. Nordgren SR, Fasth SB, Oresland TO, Hultén LA. Long-term follow-up in Crohn's disease. Mortality, morbidity, and functional status. Scand J Gastroenterol. 1994. 29:1122–1128.

206. Weston LA, Roberts PL, Schoetz DJ Jr, Coller JA, Murray JJ, Rusin LC. Ileocolic resection for acute presentation of Crohn's disease of the ileum. Dis Colon Rectum. 1996. 39:841–846.

207. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005. 11:707–712.

208. Tromm A, Tromm CD, Hüppe D, Schwegler U, Krieg M, May B. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol. 1992. 27:774–778.

209. Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol. 2005. 2:580–586.

210. Hassan C, Zullo A, De Francesco V, et al. Systematic review: Endoscopic dilatation in Crohn's disease. Aliment Pharmacol Ther. 2007. 26:1457–1464.

211. Michelassi F, Upadhyay GA. Side-to-side isoperistaltic strictureplasty in the treatment of extensive Crohn's disease. J Surg Res. 2004. 117:71–78.

212. Poggioli G, Laureti S, Pierangeli F, Ugolini F. A new model of strictureplasty for multiple and long stenoses in Crohn's ileitis: side-to-side diseased to disease-free anastomosis. Dis Colon Rectum. 2003. 46:127–130.

213. Sampietro GM, Sartani A, Danelli P, et al. Strictureplasty in the surgical treatment of complicated Crohn's disease. Ann Ital Chir. 2003. 74:659–663.

214. Shatari T, Clark MA, Yamamoto T, et al. Long strictureplasty is as safe and effective as short strictureplasty in small-bowel Crohn's disease. Colorectal Dis. 2004. 6:438–441.

215. Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD. Strictureplasty for Crohn's disease: meta-analysis. Dis Colon Rectum. 2000. 43:911–919.

216. Tonelli F, Fedi M, Paroli GM, Fazi M. Indications and results of side-to-side isoperistaltic strictureplasty in Crohn's disease. Dis Colon Rectum. 2004. 47:494–501.

217. Reese GE, Purkayastha S, Tilney HS, von Roon A, Yamamoto T, Tekkis PP. Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. 2007. 9:686–694.

218. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007. 50:1968–1986.

219. Fearnhead NS, Chowdhury R, Box B, George BD, Jewell DP, Mortensen NJ. Long-term follow-up of strictureplasty for Crohn's disease. Br J Surg. 2006. 93:475–482.

220. Fichera A, Lovadina S, Rubin M, Cimino F, Hurst RD, Michelassi F. Patterns and operative treatment of recurrent Crohn's disease: a prospective longitudinal study. Surgery. 2006. 140:649–654.

221. Menon AM, Mirza AH, Moolla S, Morton DG. Adenocarcinoma of the small bowel arising from a previous strictureplasty for Crohn's disease: report of a case. Dis Colon Rectum. 2007. 50:257–259.

222. Breysem Y, Janssens JF, Coremans G, Vantrappen G, Hendrickx G, Rutgeerts P. Endoscopic balloon dilation of colonic and ileo-colonic Crohn's strictures: long-term results. Gastrointest Endosc. 1992. 38:142–147.

223. Thomas-Gibson S, Brooker JC, Hayward CM, Shah SG, Williams CB, Saunders BP. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol. 2003. 15:485–488.

224. Broering DC, Eisenberger CF, Koch A, et al. Strictureplasty for large bowel stenosis in Crohn's disease: quality of life after surgical therapy. Int J Colorectal Dis. 2001. 16:81–87.

225. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology. 1985. 88:1818–1825.

226. McLeod RS. Surgery for inflammatory bowel diseases. Dig Dis. 2003. 21:168–179.

227. Thirlby RC, Land JC, Fenster LF, Lonborg R. Effect of surgery on health-related quality of life in patients with inflammatory bowel disease: a prospective study. Arch Surg. 1998. 133:826–832.

228. Gardiner KR, Dasari BV. Operative management of small bowel Crohn's disease. Surg Clin North Am. 2007. 87:587–610.

229. Steele SR. Operative management of Crohn's disease of the colon including anorectal disease. Surg Clin North Am. 2007. 87:611–631.

230. Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol. 2001. 32:409–412.

231. Gervais DA, Hahn PF, O'Neill MJ, Mueller PR. Percutaneous abscess drainage in Crohn disease: technical success and short- and long-term outcomes during 14 years. Radiology. 2002. 222:645–651.

232. Yamaguchi A, Matsui T, Sakurai T, et al. The clinical characteristics and outcome of intraabdominal abscess in Crohn's disease. J Gastroenterol. 2004. 39:441–448.

233. Lee H, Kim YH, Kim JH, et al. Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease. Dig Liver Dis. 2006. 38:659–664.

234. Kim DH, Cheon JH, Moon CM, et al. Clinical efficacy of nonsurgical treatment of Crohn's disease-related intraabdominal abscess. Korean J Gastroenterol. 2009. 53:29–35.

235. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990. 99:956–963.

236. Caprilli R, Andreoli A, Capurso L, et al. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Aliment Pharmacol Ther. 1994. 8:35–43.

237. Borley NR, Mortensen NJ, Jewell DP. Preventing postoperative recurrence of Crohn's disease. Br J Surg. 1997. 84:1493–1502.

238. Viscido A, Corrao G, Taddei G, Caprilli R. Gruppo Italiano per lo Studio del Colon e del Retto. "Crohn's disease activity index" is inaccurate to detect the post-operative recurrence in Crohn's disease. A GISC study. Ital J Gastroenterol Hepatol. 1999. 31:274–279.

239. Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg. 2004. 187:219–225.

240. Onali S, Petruzziello C, Calabrese E, et al. Frequency, pattern, and risk factors of postoperative recurrence of Crohn's disease after resection different from ileo-colonic. J Gastrointest Surg. 2009. 13:246–252.

241. Sachar DB, Lemmer E, Ibrahim C, et al. Recurrence patterns after first resection for stricturing or penetrating Crohn's disease. Inflamm Bowel Dis. 2009. 15:1071–1075.

242. Hofer B, Böttger T, Hernandez-Richter T, Seifert JK, Junginger T. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn's disease. Hepatogastroenterology. 2001. 48:152–155.

243. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg. 2000. 87:1697–1701.

244. Welsch T, Hinz U, Löffler T, et al. Early re-laparotomy for post-operative complications is a significant risk factor for recurrence after ileocaecal resection for Crohn's disease. Int J Colorectal Dis. 2007. 22:1043–1049.

245. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology. 1995. 109:404–413.

246. Caprilli R, Taddei G, Viscido A. In favour of prophylactic treatment for post-operative recurrence in Crohn's disease. Ital J Gastroenterol Hepatol. 1998. 30:219–225.

247. Breslin NP, Sutherland LR. The case against routine post-operative therapy for prevention of recurrence in Crohn's disease. Ital J Gastroenterol Hepatol. 1998. 30:226–230.

248. Fazio VW, Marchetti F. Recurrent Crohn's disease and resection margins: bigger is not better. Adv Surg. 1999. 32:135–168.

249. Botti F, Carrara A, Antonelli B, et al. The minimal bowel resection in Crohn's disease: analysis of prognostic factors on the surgical recurrence. Ann Ital Chir. 2003. 74:627–633.

250. Athanasiadis S, Yazigi R, Köhler A, Helmes C. Recovery rates and functional results after repair for rectovaginal fistula in Crohn's disease: a comparison of different techniques. Int J Colorectal Dis. 2007. 22:1051–1060.

251. Renna S, Cammà C, Modesto I, et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology. 2008. 135:1500–1509.

252. Sampietro GM, Corsi F, Maconi G, et al. Prospective study of long-term results and prognostic factors after conservative surgery for small bowel Crohn's disease. Clin Gastroenterol Hepatol. 2009. 7:183–191.

253. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology. 2000. 118:264–273.

254. Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther. 2003. 17:517–523.

255. Camma C, Viscido A, Latella G, Caprilli R, Cottone M. Mesalamine in the prevention of clinical and endoscopic post-operative recurrence of Crohn's disease: a meta-analysis. Dig Liver Dis. 2002. 34:A86.

256. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995. 108:1617–1621.

257. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005. 128:856–861.

258. Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut. 1984. 25:52–56.

259. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol. 1984. 6:211–216.

260. Hanan IM, Kirsner JB. Inflammatory bowel disease in the pregnant woman. Clin Perinatol. 1985. 12:669–682.

261. Choi JH, Yoo HS, Yang S, et al. The influence of inflammatory bowel disease and its treatment with 5-aminosalicylic acid on pregnancy and fetal outcome. Intest Res. 2004. 2:26–30.

262. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007. 56:830–837.

263. Fonager K, Sørensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998. 93:2426–2430.

264. Larzilliere I, Beau P. Chronic inflammatory bowel disease and pregnancy. Case control study. Gastroenterol Clin Biol. 1998. 22:1056–1060.

265. Korelitz BI. Inflammatory bowel disease and pregnancy. Gastroenterol Clin North Am. 1998. 27:213–224.

266. Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology. 1990. 99:987–994.

267. Toth A. Reversible toxic effect of salicylazosulfapyridine on semen quality. Fertil Steril. 1979. 31:538–540.

268. O'Moráin C, Smethurst P, Doré CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut. 1984. 25:1078–1084.

269. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004. 99:2385–2392.

270. Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med. 1986. 79:221–225.

271. Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981. 80:72–76.

272. Alstead EM. Inflammatory bowel disease in pregnancy. Postgrad Med J. 2002. 78:23–26.

273. Castiglione F, Pignata S, Morace F, et al. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. Ital J Gastroenterol. 1996. 28:199–204.

274. Nwokolo CU, Tan WC, Andrews HA, Allan RN. Surgical resections in parous patients with distal ileal and colonic Crohn's disease. Gut. 1994. 35:220–223.

275. Riis L, Vind I, Politi P, et al. European Collaborative Study Group on Inflammatory Bowel Disease. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol. 2006. 101:1539–1545.

276. Buyon JP. The effects of pregnancy on autoimmune diseases. J Leukoc Biol. 1998. 63:281–287.

277. Ilnyckyji A, Blanchard JF, Rawsthorne P, Bernstein CN. Perianal Crohn's disease and pregnancy: role of the mode of delivery. Am J Gastroenterol. 1999. 94:3274–3278.

278. Scott HJ, McLeod RS, Blair J, O'Connor B, Cohen Z. Ileal pouch-anal anastomosis: pregnancy, delivery and pouch function. Int J Colorectal Dis. 1996. 11:84–87.

279. Ravid A, Richard CS, Spencer LM, et al. Pregnancy, delivery, and pouch function after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2002. 45:1283–1288.

280. Nelson H, Dozois RR, Kelly KA, Malkasian GD, Wolff BG, Ilstrup DM. The effect of pregnancy and delivery on the ileal pouchanal anastomosis functions. Dis Colon Rectum. 1989. 32:384–388.

281. Nicholl MC, Thompson JM, Cocks PS. Stomas and pregnancy. Aust N Z J Obstet Gynaecol. 1993. 33:322–324.

282. Brandt LJ, Estabrook SG, Reinus JF. Results of a survey to evaluate whether vaginal delivery and episiotomy lead to perineal involvement in women with Crohn's disease. Am J Gastroenterol. 1995. 90:1918–1922.

283. Hill J, Clark A, Scott NA. Surgical treatment of acute manifestations of Crohn's disease during pregnancy. J R Soc Med. 1997. 90:64–66.

284. Subhani JM, Hamiliton MI. Review article: The management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther. 1998. 12:1039–1053.

285. Nielsen OH, Andreasson B, Bondesen S, Jacobsen O, Jarnum S. Pregnancy in Crohn's disease. Scand J Gastroenterol. 1984. 19:724–732.

286. Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2003. 32:323–340.

287. van der Woude CJ, Kolacek S, Dotan I, et al. European Crohn's Colitis Organisation (ECCO). European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010. 4:493–510.

288. Khan AK, Truelove SC. Placental and mammary transfer of sulphasalazine. Br Med J. 1979. 2:1553.

289. Marteau P, Devaux CB. Mesalazine during pregnancy. Lancet. 1994. 344:1708–1709.

290. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008. 25:271–275.

291. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995. 172:525–529.

292. Shennan A, Crawshaw S, Briley A, et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET study. BJOG. 2006. 113:65–74.

293. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998. 42:1336–1339.

294. Brumfitt W, Pursell R. Trimethoprim-sulfamethoxazole in the treatment of bacteriuria in women. J Infect Dis. 1973. 128:Suppl. 657–665.

295. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000. 62:385–392.

296. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet. 2004. 270:79–85.

297. Beaulieu DB, Ananthakrishnan AN, Issa M, et al. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm Bowel Dis. 2009. 15:25–28.

298. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 1995. 38:1722–1732.

299. Nicholson HO. Cytotoxic drugs in pregnancy. Review of reported cases. J Obstet Gynaecol Br Commonw. 1968. 75:307–312.

300. Blatt J, Mulvihill JJ, Ziegler JL, Young RC, Poplack DG. Pregnancy outcome following cancer chemotherapy. Am J Med. 1980. 69:828–832.

301. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990. 99:443–446.

302. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003. 124:9–17.

303. Roubenoff R, Hoyt J, Petri M, Hochberg MC, Hellmann DB. Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum. 1988. 18:88–110.

304. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med. 1990. 88:589–592.

305. Kane S. Managing pregnancy in IBD. Inflamm Bowel Dis Monitor. 2002. 4:2–11.

306. Smithells RW, Newman CG. Recognition of thalidomide defects. J Med Genet. 1992. 29:716–723.

307. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000. 108:487–495.

308. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005. 21:733–738.

309. Johnson DL, Jones KL, Chambers CD, Salas E. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology. 2009. 136:A27.

310. Esbjörner E, Järnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand. 1987. 76:137–142.

311. Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology. 1998. 114:23–28.

312. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology. 1993. 105:1057–1060.

313. Marteau P, Tennenbaum R, Elefant E, Lémann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther. 1998. 12:1101–1108.

314. Ost L, Wettrell G, Björkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr. 1985. 106:1008–1011.

315. Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 1972. 81:936–945.